What if there was a therapy on the market that reduced disease-specific mortality by approximately 28%, enhanced overall survival (OS) outcomes, and conferred very little in the way of adverse effects (AEs)? According to Sarah Psutka, MD, MS, urologic oncologist at the Fred Hutchinson Cancer Center and of the University of Washington, and her colleagues in the oncology space, exercise can hold the key to further optimizing favorable outcomes for patients. “The FDA would be all over it,” she explained regarding the underrealized benefits of exercise as a supplement to cancer treatment.
